Literature DB >> 2465403

Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine.

M A Harbison1, S M Hammer.   

Abstract

Eleven povidone-iodine-containing products (Betadine) and chlorhexidine gluconate solution were tested for their ability to inactivate human immunodeficiency virus (HIV) in a cell culture system. All Betadine products completely inactivated the virus at povidone-iodine concentrations of greater than or equal to 0.5% (10- to 20-fold dilutions of stock) except for Betadine Lubricating Antiseptic Gel, which required 2.5% for efficacy (1:2 dilution). Chlorhexidine gluconate completely inactivated HIV at concentrations of greater than or equal to 0.2% (1:100 dilution of laboratory stock; 1:20 dilution of commercial stock). Betadine douche and medicated douche did not inactivate HIV at the concentrations recommended for clinical use (0.33% and 0.25%, respectively) but were effective at povidone-iodine concentrations of 0.5%. Inactivation appeared to be immediate since no difference in efficacy based on length of exposure to the microbicide was detected. Thus, both microbicides are highly effective at killing HIV in vitro.

Entities:  

Keywords:  Clinical Research; Diseases; Economic Factors; Examinations And Diagnoses; Hiv Infections--prevention and control; Laboratory Examinations And Diagnoses; Laboratory Procedures; Research And Development; Research Methodology; Technology; Treatment; Viral Diseases

Mesh:

Substances:

Year:  1989        PMID: 2465403

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  9 in total

1.  Reducing surgical site infections: a review.

Authors:  David E Reichman; James A Greenberg
Journal:  Rev Obstet Gynecol       Date:  2009

2.  Lack of complications of the hydroxyapatite orbital implant in 250 consecutive cases.

Authors:  C L Shields; J A Shields; P De Potter; A D Singh
Journal:  Trans Am Ophthalmol Soc       Date:  1993

3.  Problems with the hydroxyapatite orbital implant: experience with 250 consecutive cases.

Authors:  C L Shields; J A Shields; P De Potter; A D Singh
Journal:  Br J Ophthalmol       Date:  1994-09       Impact factor: 4.638

4.  Tolerance and safety of different concentrations of chlorhexidine for peripartum vaginal and infant washes: HIVNET 025.

Authors:  Craig M Wilson; Glenda Gray; Jennifer S Read; Anthony Mwatha; Sanjay Lala; Saul Johnson; Avye Violari; Portia Mabali Sibiya; Thomas R Fleming; Ann Koonce; Sten H Vermund; James McIntyre
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

Review 5.  Viricidal treatments for prevention of coronavirus infection.

Authors:  Manoj Khokhar; Dipayan Roy; Purvi Purohit; Manu Goyal; Puneet Setia
Journal:  Pathog Glob Health       Date:  2020-09-02       Impact factor: 2.894

6.  Surgical outcomes of different Ahmed Glaucoma Valve implantation methods between scleral graft and scleral flap.

Authors:  Ho Young Lee; Jong Seok Park; Yoon Jung Choy; Hyun Joo Lee
Journal:  Korean J Ophthalmol       Date:  2011-09-20

7.  The Effects of Surgical Antiseptics and Time Delays on RNA Isolated From Human and Rodent Peripheral Nerves.

Authors:  Matthew Wilcox; Tom J Quick; James B Phillips
Journal:  Front Cell Neurosci       Date:  2019-05-22       Impact factor: 5.505

8.  Mechanisms of the action of povidone-iodine against human and avian influenza A viruses: its effects on hemagglutination and sialidase activities.

Authors:  Nongluk Sriwilaijaroen; Prapon Wilairat; Hiroaki Hiramatsu; Tadanobu Takahashi; Takashi Suzuki; Morihiro Ito; Yasuhiko Ito; Masato Tashiro; Yasuo Suzuki
Journal:  Virol J       Date:  2009-08-13       Impact factor: 4.099

9.  Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework.

Authors:  Syed H S Naqvi; Martin J Citardi; Davide Cattano; Luis Ostrosky-Zeichner; Mark I Knackstedt; Ron J Karni
Journal:  J Otolaryngol Head Neck Surg       Date:  2020-10-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.